Predicting the outcome of severe ulcerative colitis: Development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 10, 2004, Pages 1079-1087

  Ho, G T ^a   Mowat, C ^b   Goddard, C J R ^c   Fennell, J M ^a   Shah, N B ^a   Prescott, R J ^d   Satsangi, J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c ST JOHN'S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; HEPARIN; HYDROCORTISONE; MESALAZINE; METHYLPREDNISOLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COLON DILATATION; COLON RESECTION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; HYPOALBUMINEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARENTERAL NUTRITION; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; THROMBOEMBOLISM; TOPICAL TREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PATIENT SELECTION; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 2542573221     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01945.x     Document Type: Article

References (25)

1. Edward FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 2002; 4: 299-315.
2. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.
3. Buckell NA, Lennard-Jones JE. How district hospitals see acute colitis. Lancet 1979; 1: 1226-9.
4. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
5. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5.
6. Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-9.
7. Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993; 88: 852-5.
8. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-8.
9. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
10. Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 303-8.
11. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10: 411-3.
12. Stack WA, Williams D, Stevenson M, Logan RF. Immunosuppressive therapy for ulcerative colitis: results of a nationwide survey among consultant physician members of the British Society of Gastroenterology. Aliment Pharmacol Ther 1999; 13: 569-75.
13. Hawthorne AB, Travis SP. Outcome of in-patient management of severe colitis: a BSG IBD clinical network survey. Gut 2002; A059 (abstract).
14. Baert F, Hanauer S. CYA in severe steroid-resistant UC: long term results of therapy. Gastroenterology 1994; A648 (abstract).
15. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
16. Van Assche G, D' Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
17. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-92.
18. Hyde GM, Jewell DP. Review article: the management of severe ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 419-24.
19. Plevy SE, Salzberg BA, Regueiro M, et al. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: preliminary results of phase I study. Gastroenterology 2003; Abstract 62.
20. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 65-75.
21. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6.
22. Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut 1975; 16: 579-84.
23. Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 973-8.
24. Kamm MA. Antagonist: early surgical intervention in ulcerative colitis. Gut 2004; 53: 308-9.
25. Cohen RD, Brodsky AL, Hanauer S. A comparison of quality of life in patients with severe ulcerative colitis preoperatively and postoperatively. Inflamm Bowel Dis 1999; 5: 1-10.